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• Opioid use disorder (OUD) is a chronic brain disease characterized by episodes of relapse and remission. 1 • Relapse is a key outcome and quality metric in OUD treatment, but has no specific diagnosis code.
• In clinical settings, opioid relapse can be ascertained through positive urine screen results or patient self-report, but this information is not contained in claims databases.
• Claims databases offer the opportunity to study OUD treatment outcomes in large real-world samples of patients.
BACKGROUND
• Relapse rates varied widely depending on the measure used. The literature similarly includes variation in rates due to measurement differences between studies.
• Opioid relapse has not been extensively measured in claims data, although several studies identify relapse using service-based proxies. The rates reported in these studies are higher than the CM used in this study.
• While the relapse rates identified from claims databases are lower than those reported in prospective clinical and observational studies due to the lack of urinalysis and/or patient self-report data, it would be expensive and impractical to conduct prospective studies in large samples.
• The CM and IM relapse indicators from this study provide a valuable starting point for evaluating relapse in retrospective observational studies using claims data.
• The CM likely captures most relapses, but may only identify relapses that result in service utilization. 2 Some indicators included in the IM may identify additional relapses that do not result in detoxification, hospitalization, or an emergency room visit.
• This study highlights the need for a consistent definition of relapse in claims-based studies, the evidence-based utilization of defined measures, and future research targeting the validation of claims-based markers of opioid relapse. Validated claims-based markers of relapse could potentially be used not only to assess outcomes but also to identify patients at risk of relapse.
CONCLUSIONS
• OUD may be under coded in claims data; this study included only patients with a documented diagnosis of OUD on a healthcare claim.
• The study examined individuals with commercial health coverage through an employer and Medicaid beneficiaries from select states and may not be generalizable to patients with other types of coverage or with no health insurance coverage.
• Services that do not result in a medical claim being submitted to the health plan (e.g., cashpay buprenorphine treatment) cannot be measured from claims data, so were not included in this analysis.
• The results of urine drug screens were not available to assess actual opioid use following treatment initiation in the relapse assessment resulting in a lower relapse rate compared to other studies.
LIMITATIONS

Patient Characteristics
• Table 1 presents the characteristics of the Commercial and Medicaid patients included in the analysis.
RESULTS
• This study examined various approaches to measuring relapse using claims data and compared the rates to the literature to assess measure feasibility.
• A secondary objective was to initiate the process of obtaining consensus on how to define relapse in claims databases. • The databases contain the pooled medical (inpatient, outpatient) and outpatient prescription drug experience of employees and dependents covered under various employer-sponsored health plans (Commercial) or Medicaid enrollees from several geographically-dispersed states (Medicaid).
OBJECTIVES
Sample Selection and Study Period
• Patients with OUD initiating a new buprenorphine medication assisted treatment (BMAT) episode were identified; Figure 1 shows the study inclusion and exclusion criteria.
• Patients were followed for 6 months following treatment initiation to assess relapse. Research funded by Indivior Inc.
METHODS
REFERENCES Relapse Measures
• Conservative and inclusive binary relapse measures were created, based on service use measured from claims.
-The conservative measure (CM) was a modification of a measure used in prior claims-based OUD studies, 2,3 and defined relapse as the presence of one or more of the following:
• Diagnosis of continuous or episodic opioid dependence following a dependence in remission diagnosis
• Inpatient admission with a primary opioid-related diagnosis
• Emergency department visit with any opioid-related diagnosis
• Detoxification with any opioid-related diagnosis -The inclusive measure (IM) defined relapse as the presence of one or more of the following that clinician input suggested might be possible relapse indicators:
• Any service listed above under the conservative measure
• Inpatient admission with a secondary diagnosis of opioid overdose
• Pharmacy claim(s) for narcotic pain medication without indication of trauma or surgery 7 days prior
• Pharmacy claim(s) for narcotic pain medication covering >30 consecutive days
• Abruptly stopping BMAT without taper
Analysis
• Relapse rates were measured among OUD patients initiating BMAT in the MarketScan databases.
• Rates were compared to recent studies to assess feasibility of the claims-based measures.
Relapse Rates
• Figure 2 shows the percent of patients identified by each relapse indicator.
• Relapse rates 6 months post-BMAT initiation ranged from 7.1% (CM) to 38.1% (IM) in Commercial patients (N=22,563) and 6.0% (CM) to 44.0% (IM) in Medicaid patients (N=7,811).
• Among the IM indicators, abrupt discontinuation was observed in 23.1% of Commercial patients and 26.6% of Medicaid patients.
• Narcotic pain medication claims without trauma or surgery were observed among 9.5% of Commercial and 16.7% of Medicaid patients.
• Narcotic pain medication claims covering >30 consecutive days were observed among 9.4% of Commercial and 8.8% of Medicaid patients.
RESULTS (CONT'D)
Dx: diagnosis; IP: inpatient; ED: emergency department; Rx: outpatient prescription; BMAT: buprenorphine medication assisted treatment
Comparison with Literature
• Direct comparisons between relapse rates reported in the literature and the IM and CM rates observed in this study were difficult due to the variety of methods and time frames present in the literature. Table 2 highlights the findings of several recent studies.
• Little overall work has examined opioid relapse in claims-based samples, but recent claims database studies 2-3 report opioid relapse following BMAT initiation using service-based proxies comparable to the CM measure used in this study.
-The 20.7% of Massachusetts Medicaid patients who relapsed at least once during a BMAT episode (median duration of 8 months) 2 is over three times as high as the CM rate observed among Medicaid patients in the current study over a 6-month follow-up period; differing definitions and data sources may explain the disparity.
-Forty-six relapse events per 1,000 member months were observed among 10,248 Massachusetts Medicaid BMAT patients in the 6 months following treatment initiation. 3 Despite the similar follow-up period as the current study, difference in reporting make comparison to this study difficult.
• In clinical trials and prospective studies, opioid relapse is generally identified by urinalysis or patient self-reported opioid use. [4] [5] [6] [7] Treatment non-retention is sometimes used as a proxy for relapse, similar to the IM measure of abrupt discontinuation of treatment in this study.
BMAT: buprenorphine medication assisted treatment; MA: Massachusetts; RCT: randomized controlled trial; OP: outpatient; IP: inpatient; ED: emergency department
